{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:30:21Z","timestamp":1792953021686,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Child and Adolescent Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.chc.2008.06.009","type":"journal-article","created":{"date-parts":[[2008,9,7]],"date-time":"2008-09-07T15:04:56Z","timestamp":1220799896000},"page":"713-738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Treatment of Inattention, Overactivity, and Impulsiveness in Autism Spectrum Disorders"],"prefix":"10.1016","volume":"17","author":[{"given":"Michael G.","family":"Aman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristan A.","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Hollway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.Eugene","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chc.2008.06.009_bib1","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10803-006-0147-5","article-title":"Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification","volume":"36","author":"Lecavalier","year":"2006","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.009_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0891-4222(95)00039-9","article-title":"The Nisonger CBRF: a child behavior rating form for children with developmental disabilities","volume":"17","author":"Aman","year":"1996","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.chc.2008.06.009_bib3","series-title":"Psychotropic medication and developmental disabilities: the international consensus handbook","first-page":"229","article-title":"Stimulants","author":"Arnold","year":"1998"},{"key":"10.1016\/j.chc.2008.06.009_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/104454603321666171","article-title":"Methylphenidate treatment in children with low IQ and ADHD: analysis of three aggregated studies","volume":"13","author":"Aman","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.chi.0000120024.14101.96","article-title":"Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response","volume":"43","author":"Pearson","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF01538168","article-title":"Response to tri-iodothyronine and dextroamphetamine: a study of preschool schizophrenic children","volume":"2","author":"Campbell","year":"1972","journal-title":"J Autism Child Schizophr"},{"key":"10.1016\/j.chc.2008.06.009_bib7","first-page":"70","article-title":"Levodopa and levoamphetamine:a crossover study in young schizophrenic children","volume":"19","author":"Campbell","year":"1976","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.chc.2008.06.009_bib8","series-title":"Attention deficit hyperactivity disorder: from genes to patients","first-page":"487","article-title":"Psychostimulants in attention deficit hyperactivity attention deficit disorder: theoretical and practical issues for the community practitioner","author":"Connor","year":"2007"},{"issue":"4","key":"10.1016\/j.chc.2008.06.009_bib9","first-page":"605","article-title":"Effects of methylphenidate on early infantile autism and its relation to serum serotonin levels","volume":"3","author":"Hoshino","year":"1977","journal-title":"Folia Psychiatrica et Neurologica Japonica"},{"key":"10.1016\/j.chc.2008.06.009_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00004583-198803000-00020","article-title":"Methylphenidate treatment of hyperactive autistic children","volume":"27","author":"Birmaher","year":"1988","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/1044546041649011","article-title":"Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study","volume":"14","author":"Di Martino","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02179289","article-title":"Use of methylphenidate in the treatment of children with autistic disorder","volume":"25","author":"Quintana","year":"1995","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.009_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder","volume":"30","author":"Handen","year":"2000","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.009_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2214.2006.00631.x","article-title":"Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study","volume":"32","author":"Santosh","year":"2006","journal-title":"Child Care Hlth Dev"},{"key":"10.1016\/j.chc.2008.06.009_bib15","series-title":"ECDEU assessment manual of psychopharmacology (NIMH Publication 76-338)","author":"Guy","year":"1976"},{"key":"10.1016\/j.chc.2008.06.009_bib16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders","volume":"62","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.biopsych.2006.09.028","article-title":"Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures","volume":"61","author":"Posey","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib18","first-page":"485","article-title":"The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects","volume":"89","author":"Aman","year":"1985","journal-title":"Am J Ment Defic"},{"key":"10.1016\/j.chc.2008.06.009_bib19","first-page":"492","article-title":"Psychometric characteristics of the Aberrant Behavior Checklist","volume":"89","author":"Aman","year":"1985","journal-title":"Am J Ment Defic"},{"key":"10.1016\/j.chc.2008.06.009_bib20","series-title":"School-based assessments and interventions for ADD students","author":"Swanson","year":"1992"},{"key":"10.1016\/j.chc.2008.06.009_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/cap.2005.15.325","article-title":"Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders","volume":"15","author":"Jou","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00919127","article-title":"Normative data on revised Conners Parent And Teacher Rating Scales","volume":"6","author":"Goyette","year":"1978","journal-title":"J Abnorm Child Psychol"},{"key":"10.1016\/j.chc.2008.06.009_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2006.16.611","article-title":"Atomoxetine for attention-deficit\/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study","volume":"16","author":"Troost","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib24","series-title":"ADHD rating scale\u2014IV: checklists, norms, and clinical interpretations","author":"DuPaul","year":"1998"},{"key":"10.1016\/j.chc.2008.06.009_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/cap.2006.16.599","article-title":"Open-label atomoxetine for attention-deficit\/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders","volume":"16","author":"Posey","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib26","series-title":"Conners' continuous performance test\u2014II","author":"Conners","year":"2000"},{"key":"10.1016\/j.chc.2008.06.009_bib27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1176\/ajp.155.5.693","article-title":"Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder","volume":"155","author":"Spencer","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib28","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial","volume":"45","author":"Arnold","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.108.5.e83","article-title":"Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, dose-response study","volume":"108","author":"Michelson","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.chc.2008.06.009_bib30","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","article-title":"Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study","volume":"159","author":"Michelson","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib31","unstructured":"Sutton V, Milton D, Ruff D, et\u00a0al. Efficacy of atomoxetine treatment for children and adolescents with attention-deficit\/hyperactivity disorder. Paper presented at the 51st Annual Meeting American Academy of Child and Adolescent Psychiatry. Washington, DC: 2004, October."},{"key":"10.1016\/j.chc.2008.06.009_bib32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/10445460152595577","article-title":"An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder","volume":"11","author":"Spencer","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF01538170","article-title":"A single-blind evaluation of thiothixene with outpatient schizophrenic children","volume":"2","author":"Waizer","year":"1972","journal-title":"J Autism Child Schizophr"},{"key":"10.1016\/j.chc.2008.06.009_bib34","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","article-title":"Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms","volume":"141","author":"Anderson","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib35","first-page":"753","article-title":"Children's psychiatric rating scale","volume":"21","author":"Fish","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.chc.2008.06.009_bib36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study","volume":"36","author":"Campbell","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib37","series-title":"Clinical handbook of psychotropic drugs","author":"Bezchlibnyk-Butler","year":"2005"},{"key":"10.1016\/j.chc.2008.06.009_bib38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism for serious behavioral problems","volume":"347","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chc.2008.06.009_bib39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.chc.2008.06.009_bib40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10803-006-0078-1","article-title":"A crossover study of risperidone in children, adolescents and adults with mental retardation","volume":"36","author":"Hellings","year":"2006","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.009_bib41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/cap.2006.16.561","article-title":"Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study","volume":"16","author":"Troost","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib42","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study","volume":"44","author":"Troost","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib43","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.4088\/JCP.v65n1115","article-title":"A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders","volume":"65","author":"Corson","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib44","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10803-005-3306-1","article-title":"Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders","volume":"35","author":"Hardan","year":"2005","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.009_bib45","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/cap.2006.0126","article-title":"Ziprasidone in adolescents with autism: an open-label pilot study","volume":"17","author":"Malone","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/cap.2006.16.549","article-title":"Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities","volume":"16","author":"Valicenti-McDermott","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib47","first-page":"77","article-title":"A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism","volume":"53","author":"Fankhauser","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder","volume":"12","author":"Jaselskis","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/1044546041649084","article-title":"Guanfacine treatment of hyperactivity in pervasive developmental disorders: a retrospective analysis of 80 cases","volume":"14","author":"Posey","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/cap.2006.16.589","article-title":"A prospective open-trial of guanfacine in children with pervasive developmental disorders","volume":"16","author":"Scahill","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00004583-199905000-00012","article-title":"Critical review of tricyclic antidepressant use in children and adolescents","volume":"38","author":"Geller","year":"1999","journal-title":"J Am Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib52","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1176\/ajp.149.3.363","article-title":"Differential response of seven subjects with autistic disorder to clomipramine and desipramine","volume":"149","author":"Gordon","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.1993.01820180039004","article-title":"A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder","volume":"50","author":"Gordon","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib54","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00004583-199207000-00024","article-title":"Fluoxetine treatment of children and adults with autistic disorder and mental retardation","volume":"31","author":"Cook","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib55","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1176\/ajp.148.8.1089b","article-title":"Fluoxetine in autism","volume":"148","author":"Todd","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib56","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1023\/A:1026008602540","article-title":"Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial","volume":"28","author":"Fatemi","year":"1998","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.009_bib57","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/088307380001500214","article-title":"Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report","volume":"15","author":"Hollander","year":"2000","journal-title":"J Child Neurol"},{"key":"10.1016\/j.chc.2008.06.009_bib58","series-title":"Practitioner's guide to psychoactive drugs for children and adolescents","first-page":"433","article-title":"Anxiolytics, sedatives, and miscellaneous drugs","author":"Werry","year":"1999"},{"key":"10.1016\/j.chc.2008.06.009_bib59","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00004714-198904000-00009","article-title":"Clinical effect of buspirone in autistic children","volume":"9","author":"Realmuto","year":"1989","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib60","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1176\/ajp.126.6.884","article-title":"A teacher rating scale for use in drug studies with children","volume":"126","author":"Conners","year":"1969","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2008.06.009_bib61","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archfami.6.4.368","article-title":"Treatment with buspirone in a child with autism","volume":"6","author":"McCormick","year":"1997","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.chc.2008.06.009_bib62","first-page":"355","article-title":"Paradoxical reactions elicited by diazepam in children with classic autism","volume":"3","author":"Marrosu","year":"1987","journal-title":"Funct Neurol"},{"key":"10.1016\/j.chc.2008.06.009_bib63","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1176\/appi.ajp.158.7.1058","article-title":"Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain","volume":"158","author":"Perry","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib64","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/brain\/awf160","article-title":"Nicotinic receptor abnormalities in the cerebellar cortex in autism","volume":"125","author":"Lee","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.chc.2008.06.009_bib65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/104454602760386923","article-title":"A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder","volume":"12","author":"Hardan","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib66","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/bmj.325.7377.1422\/a","article-title":"Galantamine may be effective in treating autistic disorder","volume":"325","author":"Neiderhofer","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.chc.2008.06.009_bib67","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1089\/cap.2006.16.621","article-title":"A prospective, open-label trial of galantamine in autistic disorder","volume":"16","author":"Nicolson","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2008.06.009_bib68","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/08830738040190033001","article-title":"Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate","volume":"19","author":"Chez","year":"2004","journal-title":"J Child Neurol"},{"key":"10.1016\/j.chc.2008.06.009_bib69","series-title":"Conners' rating scales-revised, technical manual","author":"Conners","year":"1997"},{"key":"10.1016\/j.chc.2008.06.009_bib70","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","article-title":"Double-blind placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder","volume":"40","author":"King","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib71","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s007020050076","article-title":"Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy","volume":"105","author":"Carlsson","year":"1998","journal-title":"J Neural Transm"},{"key":"10.1016\/j.chc.2008.06.009_bib72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0887-8994(96)00218-4","article-title":"High levels of cerebrospinal fluid in Rett syndrome","volume":"15","author":"Lappalainen","year":"1996","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.chc.2008.06.009_bib73","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/cap.2006.16.517","article-title":"A prospective, open-label, trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders","volume":"16","author":"Owley","year":"2006","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib74","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00213-006-0518-9","article-title":"A retrospective study of memantine in children and adolescents with pervasive developmental disorders","volume":"191","author":"Erickson","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.chc.2008.06.009_bib75","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4088\/JCP.v62n07a05","article-title":"An open trial of divalproex sodium in autistic disorder spectrum disorders","volume":"62","author":"Hollander","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib76","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/s-2008-1073041","article-title":"Intractable epilepsy in children: the efficacy of lamotrigine treatment including nonsiezure-related benefits","volume":"25","author":"Uvebrant","year":"1994","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.chc.2008.06.009_bib77","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized double-blind, placebo-controlled trial","volume":"31","author":"Belsito","year":"2001","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.009_bib78","series-title":"Autism behavior checklist record form","author":"Krug","year":"1993"},{"key":"10.1016\/j.chc.2008.06.009_bib79","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/cap.2004.14.426","article-title":"A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders","volume":"14","author":"Hardan","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.009_bib80","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00004583-198903000-00009","article-title":"Naltrexone in autistic children: an acute open dose range tolerance trial","volume":"28","author":"Campbell","year":"1989","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib81","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/00004583-199311000-00024","article-title":"Naltrexone in autistic children: behavioral symptoms and attentional learning","volume":"32","author":"Campbell","year":"1993","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib82","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004583-199502000-00018","article-title":"Naltrexone in young autistic children: a double-blind placebo-controlled crossover study","volume":"34","author":"Kolmen","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib83","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-1781(95)02749-M","article-title":"Placebo-controlled acute dosage naltrexone study in young autistic children","volume":"58","author":"Willemsen-Swinkles","year":"1995","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.chc.2008.06.009_bib84","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0006-3223(95)00297-9","article-title":"The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo controlled crossover study","volume":"39","author":"Willemsen-Swinkles","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib85","first-page":"1570","article-title":"Naltrexone in young autistic children: replication study and learning measures","volume":"36","author":"Kolmen","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.009_bib86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1023000929040","article-title":"Brief report: six months continuation treatment in naltrexone-responsive children with autism: a double blind placebo-controlled crossover study","volume":"29","author":"Willemsen-Swinkles","year":"1999","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.009_bib87","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1023\/A:1005559725475","article-title":"Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders","volume":"30","author":"Aman","year":"2000","journal-title":"J Autism Dev Disord"}],"container-title":["Child and Adolescent Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499308000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499308000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:38:25Z","timestamp":1760999905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056499308000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1056499308000394"],"URL":"https:\/\/doi.org\/10.1016\/j.chc.2008.06.009","relation":{},"ISSN":["1056-4993"],"issn-type":[{"value":"1056-4993","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Inattention, Overactivity, and Impulsiveness in Autism Spectrum Disorders","name":"articletitle","label":"Article Title"},{"value":"Child and Adolescent Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chc.2008.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}